Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.
1. A composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD), wherein the CBDV and CBD are present in a ratio of from 7:1 to 1:2 (CBDV:CBD).
2. A composition as claimed in claim 1 , further comprising one or more excipients.
3. A composition as claimed in claim 1 , which further comprises at least one non-cannabinoid component of cannabis.
4. A composition as claimed in claim 3 , wherein the at least one non-cannabinoid component of cannabis is or comprises a terpene.
5. A composition as claimed in claim 1 , wherein the phytocannabinoids comprise, or consist essentially of CBDV, CBD and one or more cannabichromene type compounds.
6. A composition as claimed in claim 5 , wherein the one or more cannabichromene type compounds is cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).
7. A composition as claimed in claim 1 , which is absent or substantially absent of any other cannabinoids.
8. A composition as claimed in claim 7 , wherein the any other cannabinoids are tetrahydrocannabivarin (THCV) and/or tetrahydrocannabinol (THC).
9. A composition as claimed in claim 1 , wherein a unit dosage form comprises from 500 to 2000 mg CBDV.
10. A composition as claimed in claim 1 , wherein a unit dosage form comprises from 100 to 600 mg CBD.
11. A composition as claimed in claim 1 , further comprising a standard anti-epileptic drug (SAED).
12. A composition consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD), wherein the CBDV and CBD are present in a ratio of from 7:1 to 1:2 (CBDV:CBD).
13. A composition as claimed in claim 12 , further comprising one or more excipients.
14. A composition as claimed in claim 12 , which further comprises at least one non-cannabinoid component of cannabis.
15. A composition as claimed in claim 14 , wherein the at least one non-cannabinoid component of cannabis is or comprises a terpene.
16. A composition as claimed in claim 12 , wherein the phytocannabinoids comprise, or consist essentially of CBDV, CBD and one or more cannabichromene type compounds.
17. A composition as claimed in claim 16 , wherein the one or more cannabichromene type compounds is cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).
18. A composition as claimed in claim 12 , which is absent or substantially absent of any other cannabinoids.
19. A composition as claimed in claim 18 , wherein the any other cannabinoids are tetrahydrocannabivarin (THCV) and/or tetrahydrocannabinol (THC).
20. A composition as claimed in claim 12 , wherein a unit dosage form comprises from 500 to 2000 mg CBDV.
21. A composition as claimed in claim 12 , wherein a unit dosage form comprises from 100 to 600 mg CBD.
22. A composition as claimed in claim 12 , further comprising a standard anti-epileptic drug (SAED).